Investigational drug · Phase 3
ATG-022
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "ATG-022"
First trial start
2026
Feb 27, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ATG-022", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Approved drugs for the same conditions: Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "ATG-022" as an intervention, largest first.
- A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction AdenocarcinomaPivotal-lookingRecruiting
Antengene Biologics LimitedIndustry
NCT07795346 · 380 participants (planned) · Start Sep 17, 2026 · Primary completion Dec 31, 2029
Drug: ATG-022; Docetaxel or Irinotecan · For: Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Sites: Bengbu, China; Fuyang, China; Hefei, China · 131 sites in all
Antengene Biologics LimitedIndustry
NCT05718895 · 156 participants (planned) · Start Mar 27, 2023 · Primary completion Dec 30, 2027
Drug: ATG-022 · For: Advanced/Metastatic Solid Tumors
Sites: Adelaide, Australia; Malvern, Australia; South Brisbane, Australia · 22 sites in all
Antengene Biologics LimitedIndustry
NCT07327229 · 132 participants (planned) · Start Feb 27, 2026 · Primary completion Sep 30, 2027
Drug: ATG-022; pembrolizumab/KEYTRUDA® and 1 more · For: Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Sites: Hefei, China; Beijing, China; Fuzhou, China · 30 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- RC118RC118-ADCPhase 32 trials
RemeGen Co., Ltd. · Advanced Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.